Verapamil adminis- tration in variant angina pectoris. Efficacy shown by ecg monitoring. JAMA. 1981;245:1849 51. 860. Alderman MH, Cohen H, Roque R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hyper- tensive patients. Lancet. 1997;349:594 8. 861. Parmley WW, Nesto RW, Singh BN, et al. Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. N-CAP Study Group. J Am Coll Cardiol. 1992; 19:1380 9. 862. Tatti P, Pahor M, Byington RP, et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care. 1998;21:597 603. 863. Gori T, Di Stolfo G, Sicuro S, et al. Nitroglycerin protects the endo- thelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:145 50. 864. Dawn B, Bolli R. Role of nitric oxide in myocardial preconditioning. Ann N Y Acad Sci. 2002;962:18 41. 865. Jneid H, Chandra M, Alshaher M, et al. Delayed preconditioning- mimetic actions of nitroglycerin in patients undergoing exercise tol- erance tests. Circulation. 2005;111:2565 71. 866. Parker JD, Parker JO. Nitrate therapy for stable angina pectoris. N Engl J Med. 1998;338:520 31. 867. Bottcher M, Madsen MM, Randsbaek F, et al. Effect of oral nitroglyc- erin and cold stress on myocardial perfusion in areas subtended by stenosed and nonstenosed coronary arteries. Am J Cardiol. 2002;89: 1019 24. 868. Munzel T, Mulsch A, Kleschyov A. Mechanisms underlying nitroglyc- erin-induced superoxide production in platelets: some insight, more questions. Circulation. 2002;106:170 2. 869. Lacoste LL, Theroux P, Lidon RM, et al. Antithrombotic properties of transdermal nitroglycerin in stable angina pectoris. Am J Cardiol. 1994;73:1058 62. 870. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618 28. 871. Gori T, Parker JD. 